nfr-logonfr-logo
PROJECT BANK
Switch to English
Statistics
Projects

0 projects

Date from new to old

EIC-The European Innovation Council (EIC)

Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination

Cancer ranks as a major cause of death, with 3.4 million new incidences in 2020 in Europe. The current cancer standards of care include surgery, chemotherapy, radiotherapy and, as of late, immunotherapy, none of which have met their expected therapeutic outcome yet. Photomedical treatments like p...

Awarded: NOK 21.0 mill.

Project Period: 2025-2029

Location: Oslo

CL1-Health

A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of Alzheimer's Disease

FluiDx-AD aims to transform Alzheimer’s disease (AD) diagnosis and prepare the EU healthcare systems for the emergence of new AD therapies, with a 1st-in-class trio of In Vitro Diagnostics tests. FluiDx-AD tests detect a unique and proprietary suite of biomarkers in simple bodily fluids (saliva, ...

Awarded: NOK 58.5 mill.

Project Period: 2024-2028

Location: Oslo

ERC-European Research Council (ERC)

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Awarded: NOK 1.7 mill.

Project Period: 2023-2025

Location: Oslo og 2 andre

CL1-Health

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Awarded: NOK 18.2 mill.

Project Period: 2023-2028

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.

Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, h...

Awarded: NOK 2.9 mill.

Project Period: 2023-2026

Location: Oslo

CL1-Health

Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal suppo...

Awarded: NOK 23.2 mill.

Project Period: 2022-2027

Location: Telemark og 3 andre

CL1-Health

Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training.

Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training.

Awarded: NOK 34.8 mill.

Project Period: 2022-2026

Location: Oslo og 2 andre

H20-MSCA-Marie Sklodowska-Curie actions

SWIPT- MED: Simultaneous Wireless Information and Power Transfer for Medical Implants

SWIPT- MED: Simultaneous Wireless Information and Power Transfer for Medical Implants

Awarded: NOK 3.0 mill.

Project Period: 2021-2024

Location: Oslo

H20-HEALTH-Health, demographic change and wellbeing

Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment.

Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment.

Awarded: NOK 64.0 mill.

Project Period: 2021-2026

Location: Oslo og 2 andre

H20-MSCA-Marie Sklodowska-Curie actions

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Glioblastoma is not only the most frequent but also the most malignant tumour originating in the Central Nervous System. Due to the extremely complex and heterogeneous molecular biology of this tumour “the same treatment for all” approach does not work well in this disease, and standard of care i...

Awarded: NOK 2.1 mill.

Project Period: 2019-2021

Location: Oslo

H20-FET-Future and Emerging Technologies

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limited by their insufficient depth of light penetration into tissue. Cur...

Awarded: NOK 18.8 mill.

Project Period: 2019-2024

Location: Oslo og 2 andre

H20-ERC-European Research Council

Imaging Perfusion Restrictions from Extracellular Solid Stress

Even the perfect cancer drug must reach its target to have an effect. The ImPRESS project main objective is to develop a novel imaging paradigm coined Restricted Perfusion Imaging (RPI) to reveal - for the first time in humans - vascular restrictions in solid cancers caused by mechanical solid st...

Awarded: NOK 14.0 mill.

Project Period: 2018-2023

Location: Oslo

H20-MSCA-Marie Sklodowska-Curie actions

High Performance Soft-tissue Navigation

High Performance Soft-tissue Navigation

Awarded: NOK 15.0 mill.

Project Period: 2016-2021

Location: Oslo og 2 andre

H20-FET-Future and Emerging Technologies

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours

Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evalua...

Awarded: NOK 14.5 mill.

Project Period: 2016-2022

Location: Oslo

H20-MSCA-Marie Sklodowska-Curie actions

Wireless In-Body Environment

Wireless In-Body Environment

Awarded: NOK 12.2 mill.

Project Period: 2016-2019

Location: Oslo og 2 andre

1